InsidersTradesSigma
Total declarations
Company
▲ Purchases (18 ops.)
▼ Sales (27 ops.)
Insider track record
Board DirectorDisclosed buys
18
Disclosed sells
27
T+90 hit rate
0%
T+90 mean return
-27.8%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by TREACE JAMES T, Director. Officer active across 1 company, notably Treace Medical Concepts, INC.. Cumulatively, 55 reports have been recorded. Breakdown: 18 buys · 27 sells. Total volume traded: €19.6m. History available since 20 October 2021. The latest transaction was disclosed on 12 May 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations55 total
43,000 shares@ US$2.17390.046% mcap1.5% of flowCommon StockSEC:0001193125-26-224391:0
Canonical exit: 10 Aug 2026 (T+90)
2,062 shares0Common StockSEC:0001193125-26-102762:0
14,254 shares0Common StockSEC:0001193125-26-021449:0
13,219 shares0Common StockSEC:0001193125-26-012080:0
2,063 shares0Common StockSEC:0000950170-25-037574:0
60,000 shares@ US$8.73444.9% of flowCommon StockSEC:0000950170-25-032626:0
Canonical exit: 2 Jun 2025 (T+90)
225,000 shares0Common StockSEC:0000950170-25-008971:0
11,905 shares0Common StockSEC:0000950170-25-005577:0
50,000 shares@ US$5.31262.3% of flowCommon StockSEC:0000950170-24-107401:0
Canonical exit: 15 Dec 2024 (T+90)
84,000 shares@ US$5.96473.1% of flowCommon StockSEC:0000950170-24-098286:0
Canonical exit: 13 Nov 2024 (T+90)
85,000 shares@ US$6.00374.5% of flowCommon StockSEC:0000950170-24-097694:0
Canonical exit: 12 Nov 2024 (T+90)
45,000 shares@ US$5.882.4% of flowCommon StockSEC:0000950170-24-072078:0
Canonical exit: 9 Sept 2024 (T+90)
25,000 shares@ US$6.05310.9% of flowCommon StockSEC:0000950170-24-068023:0
Canonical exit: 29 Aug 2024 (T+90)
25,000 shares@ US$5.20250.8% of flowCommon StockSEC:0000950170-24-066745:0
Canonical exit: 27 Aug 2024 (T+90)
50,000 shares@ US$5.06951.6% of flowCommon StockSEC:0000950170-24-065984:0
Canonical exit: 26 Aug 2024 (T+90)
100,000 shares@ US$5.56175.0% of flowCommon StockSEC:0000950170-24-062435:0
Canonical exit: 15 Aug 2024 (T+90)
150,000 shares@ US$5.11876.9% of flowCommon StockSEC:0000950170-24-059854:0
Canonical exit: 12 Aug 2024 (T+90)
150,000 shares@ US$4.57926.2% of flowCommon StockSEC:0000950170-24-058878:0
Canonical exit: 8 Aug 2024 (T+90)
83,000 shares@ US$4.53042.4% of flowCommon StockSEC:0000950170-24-058986:0
Canonical exit: 8 Aug 2024 (T+90)
46,500 shares@ US$20.126.1% of flowCommon StockSEC:0000950170-24-038822:0
2,064 shares0Common StockSEC:0000950170-24-030472:0
178,325 shares0Common StockSEC:0001209191-24-001590:0
40,000 shares@ US$25.00666.1% of flowCommon StockSEC:0001209191-23-026796:0
50,000 shares@ US$25.86348.0% of flowCommon StockSEC:0001209191-23-021955:0
2,075 shares@ US$24.410.5% of flowCommon StockSEC:0001209191-23-018046:0
25 of 55 declarations
About TREACE JAMES T
James T. Treace is an executive at Treace Medical Concepts, Inc.
